This is the authors' abstract. We don't add key points for this paper.
Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, has been approved as a treatment for ALK-positive lung cancer. This review provides information regarding the pharmacology and clinical features of lorlatinib, including its efficacy and associated adverse events. Pivotal clinical trials are discussed along with the current status of lorlatinib as a treatment for ALK-positive lung cancer and future therapeutic challenges.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Baba et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: